Drugs / SeVRSV
last change Feb 2019 re-read 3 minutes ago

SeVRSV

Vaccine

Developed for
respiratory syncytial virus infectious disease
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03473002 May 2018 → Feb 2019 respiratory syncytial virus infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as SeVRSV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03473002 ↗
Modality Vaccine “SeVRSV vaccine” NCT03473002 ↗